mwb research raises target to EUR 46.00: Fresenius Medical Care stock gains 2.19 percent

Published on 10/15/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On October 15, 2026, Fresenius Medical Care stock costs EUR 39.14. The quote is 2.19 percent above Xetra's close, with results due November 3, 2026.

Analyst view and reporting calendar

mwb research lifted its rating to Buy and its target to EUR 46.00 on October 14, 2026.
The research note cut its 2026 revenue estimate to EUR 19.04 billion.
Fresenius Medical Care stock trades at EUR 39.14 at 11:06 a.m. CEST at Lang & Schwarz on October 15, 2026, 2.19 percent above the Xetra close of October 14, 2026.
Third-quarter results are scheduled for November 3, 2026.

Moderner Dialyseraum mit Hämodialysegeräten und Patientenliegen bei Tageslicht — Ein fotorealistisches Bild eines modernen Dialyseraums mit mehreren Hämodialysegeräten und Patientenliegen in Reihe, ruhigem Tageslicht durch große Fenster – typisch für die Behandlungszentren von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) stock trades at EUR 39.14 at Lang & Schwarz on October 15, 2026 at 11:06 a.m. CEST, plus 2.19 percent versus the Xetra close of October 14, 2026 (EUR 38.30). According to FinanzNachrichten, mwb research raised its rating from Hold to Buy and its price target from EUR 44.00 to EUR 46.00 on October 14, 2026.

What does the EUR 46.00 target imply?

The target stands 17.53 percent above the Lang & Schwarz price. The note also confirmed Fresenius Medical Care's 2026 outlook while cutting its 2026 revenue estimate by 2.5 percent to EUR 19.04 billion and its EBIT estimate by 10.7 percent to EUR 1.66 billion, according to FinanzNachrichten. The combination points to a split investor picture: operational efficiency and share buybacks support the case, while weaker US treatment volumes and fading TDAPA effects weigh on the second half.

Three events shape the timeline

The company newsroom records a China strategy update on September 25, 2026 and the appointment of Shervin J. Korangy as chief executive on October 7, 2026, according to Fresenius Medical Care. The current timeline event is the October 14, 2026 mwb research upgrade and target increase documented by FinanzNachrichten.

Fresenius Medical Care's investor calendar sets a reporting quiet period from October 20 to November 2, 2026, followed by third-quarter results on November 3, 2026, according to Fresenius Medical Care. That date gives the new rating a clear test: management's update will show whether cost savings can offset the pressure identified in the analyst note.

FMC stock after the upgrade

The stock was trading at EUR 39.14 at Lang & Schwarz on October 15, 2026 at 11:06 a.m. CEST, 2.19 percent above the Xetra close of October 14, 2026 at EUR 38.30. The latest finance quote put market capitalization at EUR 10.4 billion and the 52-week range at EUR 34.57 to EUR 47.54 as of October 15, 2026. The research target therefore implies a 17.53 percent premium to the current euro quote, while the scheduled November report offers the next company-specific checkpoint. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.